Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A
Brierley CK. et al, (2025), Nature Genetics
Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AML.
Wang Z. et al, (2025), Blood
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial.
McIlroy G. et al, (2025), BMC Cancer, 25
Molecular profiling in MPN: who should have it and why?
Chee A. and Mead AJ., (2024), Hematology Am Soc Hematol Educ Program, 2024, 524 - 534
Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary.
Harrison CN. et al, (2024), Future Oncol, 20, 3365 - 3376
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.
Li R. et al, (2024), Sci Transl Med, 16
Predictive Performance of Cardiovascular Risk Scores in Cancer Survivors From the UK Biobank.
McCracken C. et al, (2024), JACC CardioOncol, 6, 575 - 588
Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practice.
Godfrey AL. et al, (2024), Br J Haematol
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.
Gerds AT. et al, (2024), Blood Adv
Alternative platelet differentiation pathways initiated by nonhierarchically related hematopoietic stem cells.
Carrelha J. et al, (2024), Nat Immunol
Backtracking to the future: unraveling the origins of childhood leukemia.
de Smith AJ. et al, (2024), Leukemia, 38, 416 - 419
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
Oh ST. et al, (2024), EJHaem, 5, 105 - 116
Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
Riva SG. et al, (2024), BLOOD, 144, 2525 - 2526
Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
Wang Z. et al, (2024), BLOOD, 144, 2749 - 2751
Implementing human bone marrow organoids to interrogate microenvironmental influences on the efficacy of blood cancer immunotherapies
Wong ZC. et al, (2024), CANCER RESEARCH, 84
Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib
Mead AJ. et al, (2024), BLOOD, 144, 3186 - 3187
KLF5 Is a Key Regulator of IMiD-Induced Neutropenia
Karali CS. et al, (2024), BLOOD, 144, 2527 - 2528
Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
Rampotas A. et al, (2024), BLOOD, 144, 1804 - 1806